KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Equity Ratio for 16 consecutive years, with 0.02 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 89.04% to 0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.02 through Dec 2025, down 89.04% year-over-year, with the annual reading at 0.02 for FY2025, 89.04% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.02 at Halozyme Therapeutics, down from 0.23 in the prior quarter.
  • The five-year high for Equity Ratio was 0.24 in Q3 2021, with the low at 0.02 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.13, with a median of 0.14 recorded in 2024.
  • The sharpest move saw Equity Ratio skyrocketed 264.64% in 2024, then tumbled 89.04% in 2025.
  • Over 5 years, Equity Ratio stood at 0.18 in 2021, then plummeted by 48.29% to 0.09 in 2022, then plummeted by 47.56% to 0.05 in 2023, then surged by 264.64% to 0.18 in 2024, then plummeted by 89.04% to 0.02 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.02, 0.23, and 0.16 for Q4 2025, Q3 2025, and Q2 2025 respectively.